To date, two classes of drugs modulating the NO/cGMP pathway have been approved in pulmonary arterial hypertension treatment: phosphodiesterase type 5 (PDE5) inhibitors and the soluble guanylate cyclase stimulator (sGC). The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.